Prognosis of Immune-related Adverse Events in Patients With Advanced Gastric Cancer Treated With Nivolumab or Pembrolizumab: A Multicenter Retrospective Analysis.

MLA

Ando, Takayuki, et al. “Prognosis of Immune-Related Adverse Events in Patients With Advanced Gastric Cancer Treated With Nivolumab or Pembrolizumab: A Multicenter Retrospective Analysis.” In Vivo (Athens, Greece), vol. 35, no. 1, Jan. 2021, pp. 475–82. EBSCOhost, https://doi.org/10.21873/invivo.12281.

APA

Ando, T., Ueda, A., Ogawa, K., Motoo, I., Kajiura, S., Nakajima, T., Hirano, K., Okumura, T., Tsukada, K., Hara, T., Suzuki, N., Nakada, N., Horikawa, N., Fujii, T., & Yasuda, I. (2021). Prognosis of Immune-related Adverse Events in Patients With Advanced Gastric Cancer Treated With Nivolumab or Pembrolizumab: A Multicenter Retrospective Analysis. In Vivo (Athens, Greece), 35(1), 475–482. https://doi.org/10.21873/invivo.12281

Chicago

Ando, Takayuki, Akira Ueda, Kohei Ogawa, Iori Motoo, Shinya Kajiura, Takahiko Nakajima, Katsuhisa Hirano, et al. 2021. “Prognosis of Immune-Related Adverse Events in Patients With Advanced Gastric Cancer Treated With Nivolumab or Pembrolizumab: A Multicenter Retrospective Analysis.” In Vivo (Athens, Greece) 35 (1): 475–82. doi:10.21873/invivo.12281.